Carroll Financial Associates’s XBiotech XBIT Stock Holding History

Carroll Financial Associates’s Portfolio XBIT Stock Details XBIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$1K	–	1786
2020 Q4	$1K	Buy	+100	New	+$1.84K	﹤0.01%	1493

Other funds holding XBIT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Carroll Financial Associates's XBIT Position: Q1 2021 in Review

Carroll Financial Associates sold out of XBiotech (XBIT) in Q1 2021, closing a stake of 100 shares — an estimated $1K sold.

Carroll Financial Associates first reported a position in XBIT in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 65 funds tracked by Wall St. Rank hold XBIT as of Q1 2021.

Carroll Financial Associates reported no remaining XBiotech position as of Q1 2021 after selling out during the quarter.
Carroll Financial Associates sold 100 XBiotech shares in Q1 2021, an estimated $1K.
Carroll Financial Associates first reported a position in XBiotech in Q4 2020 and held it in 1 quarter.
Carroll Financial Associates's XBiotech position peaked at $1K in Q4 2020.
65 funds tracked by Wall St. Rank held XBiotech as of Q1 2021.

Based on Carroll Financial Associates's 13F filing for Q1 2021, filed 6 Apr 2021.